ATF6α promotes prostate cancer progression by enhancing PLA2G4A‐mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis

Background Despite the clinical success of androgen receptor (AR)‐targeted therapies, prostate cancer (PCa) inevitably progresses to castration‐resistant prostate cancer (CRPC). Transcription factor 6 α (ATF6α), an effector of the unfolded protein response (UPR) that modulates the cellular response...

Full description

Saved in:

Bibliographic Details
Published in:	The Prostate Vol. 82; no. 5; pp. 617 - 629
Main Authors:	Zhao, Ru, Lv, Ye, Feng, Tingting, Zhang, Ruojia, Ge, Luna, Pan, Jihong, Han, Bo, Song, Guanhua, Wang, Lin
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01.04.2022 John Wiley and Sons Inc
Subjects:	Androgen Antagonists - therapeutic use Androgen receptors Androgens Arachidonic acid Arachidonic Acid - therapeutic use ATF6α Castration Cell death Cell Line, Tumor Chromatin CRPC Dinoprostone Endoplasmic reticulum Ferroptosis Group IV Phospholipases A2 Humans Immunoprecipitation Male Metastases Neoplasm Recurrence, Local Original PGE2 Phenotypes PLA2G4A Polymerase chain reaction Prostaglandin E2 Prostate cancer Prostatic Neoplasms, Castration-Resistant - drug therapy Protein folding Receptors, Androgen - metabolism Tumor cells AA PGE2 PLA2G4A ferroptosis ATF6α CRPC
ISSN:	0270-4137, 1097-0045, 1097-0045
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!